MedPath

Error parsing response

Error occurred while parsing the model response.

Error occurred while parsing the model response.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

Related Topics

SpringWorks Therapeutics Achieves Significant Milestones and Financial Growth in 2024

SpringWorks Therapeutics, Inc. (SWTX) has reported a notable increase in its Relative Strength (RS) Rating and shared preliminary financial results for the fourth quarter and full year of 2024. The company also highlighted advancements in its clinical trials and product portfolio, including significant progress with OGSIVEO® (nirogacestat) and mirdametinib.

Nimbus Therapeutics Advances Oncology Pipeline with WRN Inhibitor NDI-219216

Nimbus Therapeutics has completed its IND submission for NDI-219216, a non-covalent WRN inhibitor, planned for a clinical trial in H1 2025.

Revumenib Shows Promise in Phase 2 Trial for Relapsed/Refractory AML

Syndax Pharmaceuticals' revumenib demonstrated a 23% complete remission rate in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia (AML).

SpringWorks Therapeutics Reports Strong OGSIVEO Growth and Mirdametinib Regulatory Progress

SpringWorks Therapeutics reported $49.3 million in OGSIVEO® (nirogacestat) net product revenue for the third quarter of 2024, marking a 23% increase over the previous quarter.

Mirdametinib Shows Promise in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Mirdametinib demonstrates significant objective response rates and a manageable safety profile in both adult and pediatric patients with NF1-PN.

Palatin Technologies Completes Enrollment in Phase 2 Obesity Trial of Bremelanotide with Tirzepatide

Palatin Technologies has finished enrolling patients in its Phase 2 clinical trial evaluating bremelanotide co-administered with tirzepatide for obesity treatment.

Palatin Technologies Completes Enrollment in Phase 2 Obesity Trial of Bremelanotide and Tirzepatide Combination

Palatin Technologies has finished enrolling patients in its Phase 2 clinical trial evaluating bremelanotide with tirzepatide for obesity treatment.

Mirdametinib's NDA for NF1-PN Granted Priority Review by FDA

The FDA has granted priority review to SpringWorks Therapeutics' NDA for mirdametinib in treating Neurofibromatosis Type 1-associated plexiform neurofibromas (NF1-PN).

SpringWorks Therapeutics Submits NDA for Mirdametinib in NF1-Associated Plexiform Neurofibromas

SpringWorks Therapeutics has completed its NDA submission to the FDA for mirdametinib, targeting pediatric and adult patients with NF1-PN.

Reference News

[1]
SpringWorks Therapeutics Announces Mirdametinib Data to be
globenewswire.com · Nov 11, 2024
[2]
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 ... - Stock Titan
stocktitan.net · Nov 11, 2024

SpringWorks Therapeutics announced positive mirdametinib data from its ReNeu trial, showing deep and sustained tumor vol...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy